Ellington Management Group’s Juno Therapeutics, Inc. JUNO Stock Holding History

Ellington Management Group’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-10,500	Closed	-$198K	–	973
2016 Q4	$198K	Buy	+10,500	New	+$257K	0.03%	445
2016 Q1	–	Sell	-10,300	Closed	-$453K	–	814
2015 Q4	$453K	Buy	+10,300	New	+$511K	0.16%	153
2015 Q3	–	Sell	-9,897	Closed	-$528K	–	1006
2015 Q2	$528K	Buy	+9,897	New	+$525K	0.13%	227

Other funds holding JUNO

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BCM

Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Ellington Management Group's JUNO Position: Q1 2017 in Review

Ellington Management Group sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2017, closing a stake of 10,500 shares — an estimated $198K sold.

Ellington Management Group first reported a position in JUNO in Q2 2015 and held it in 3 quarters. The position peaked at $528K in Q2 2015. 157 funds tracked by Wall St. Rank hold JUNO as of Q1 2017.

Ellington Management Group reported no remaining Juno Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
Ellington Management Group sold 10,500 Juno Therapeutics, Inc. shares in Q1 2017, an estimated $198K.
Ellington Management Group first reported a position in Juno Therapeutics, Inc. in Q2 2015 and held it in 3 quarters.
Ellington Management Group's Juno Therapeutics, Inc. position peaked at $528K in Q2 2015.
157 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2017.

Based on Ellington Management Group's 13F filing for Q1 2017, filed 15 May 2017.